Jeff Lyons joined ILTOO in 2021. Over his career, Jeff has focused primarily on technology commercialisation and management of technology related businesses with a deep science component. His career has spanned from working with scientists from the Jet Propulsion Laboratory of NASA to develop a high-performance optical system which flew aboard the Space Shuttle to developing nanoscale metrology technologies from Oxford UK for the high volume semiconductor manufacturing industry. Most recently Jeff has pioneered the commercial use of a galvanic chemical process for making precision mirrors at high volume for the rapidly growing optical communications industry. Jeff joins ILTOO at a time when the commercialisation of its therapies and manufacturing of its breakthrough treatment is of critical importance.
David joined the company in 2017 as Senior Clinical Project Manager. He has more than 20 years of experience in clinical development in the pharmaceutical industry such as Aventis, Pierre Fabre Oncology and Roche. He has over the years managed various clinical programs from first-in-human studies to large phase III clinical trials, addressing a wide range of therapeutic areas and leading teams, notably in oncology.
David holds a master’s degree in Cellular Biology and Physiology from the University of Rouen.
Dominique joined the company in 2017 as Head of Pharmaceutical Operations to manage manufacturing and supply chain activities. She has more than 20 years of experience in the biotech industry contributing to the development of protein-based therapies and vaccines with Cellectis, InnaVirVax or Nautilus Biotech. She developed strong skills in leading R&D programs from bench to clinics in compliance with current quality requirements (GxP).
Dominique holds a Master Degree in Life Sciences with a specialization in pharmaceutical development from the Conservatoire National des Arts et Métiers (Paris).
Michel accompanies ILTOO Pharma since 2013. In 2005, he initiated its consulting activities to biotech companies for the development and industrialization of manufacturing processes for biologics. He spent most of his career at Eurogentec, the very first European biotech companies that he joined in 1987. He led the development of veterinary vaccines and then the conversion of the company into a service provider for the manufacturing of biologics dedicated to human use. He was head of biomanufacturing department, developed more than 30 drugs/processes and accompanied more than 30 clients. Michel received his PhD in Microbiology from the University of Liège (Belgium). His interest as a researcher at the university and at the Nuclear Study Center was the transfer and expression of genes.